Break Through to New Insights

AVISE SLE Monitor is a unique laboratory monitoring tool leveraging the power of Erythrocyte Bound C4d (EC4d) to help assess patients with SLE

AVISE SLE Monitor offers greater precision with:

  • EC4d: SLE disease activity biomarker measuring deposits resulting from complement activation1
  • Anti-C1q: SLE disease activity and lupus nephritis monitoring marker3-4
  • Anti-dsDNA by CIA: Sensitive biomarker with superior association with disease activity compared to other methods 5-6
  • C3/C4: Major proteins of the complement process playing a key role in the inflammatory and immune system

AVISE SLE Monitor incorporates a powerful combination of disease activity markers to provide actionable results

EC4d Anti-C1q Anti-dsDNA by CIA
Erythrocyte-bound C4d (EC4d) measured by flow cytometry has been shown to significantly correlate with disease activity as measured by the clinical (non-immunological) SELENA-SLEDAI (p<0.01), SF-36 (p<0.01), and BILAG-2004 (p<0.05).1,3 EC4d is a stable biomarker to assess complement activation. Antibody levels to C1q have been shown to be significantly associated with clinical SELENA-SLEDAI values (p<0.05), lupus nephritis and proteinuria (p<0.01).3-4 Anti-C1q is a laboratory developed test validated by Exagen Diagnostics. The method of anti-dsDNA reported on the AVISE SLE Monitor test is a quantitative calibrated assay with an expanded dynamic range. This assay has demonstrated superior agreement with the Farr assay as well as correlation to disease activity, compared to other anti-dsDNA methods. 5-6
graph showing EC4d levels over time Graph showing Anti-C1q over time graph charting anti-dsDNA levels over time

Request more information on AVISE® testing

Pin It on Pinterest

Share This